Evidence map›Paper›PMID 41268900›Full record

ArticleHistology and histopathology2026

Regulation of G Protein Signaling 14 protects against cerebral ischemic reperfusion injury by inhibiting the TAK1-JNK/p38 signaling pathway.

Gang Zhou, Changquan Wang, Wenyi Bai, Ju Gao, Yugao Liao, Lei Wang, Xiangbo Wu, Yu Tian, Guanglin Wang, Guangming Xia and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gang Zhou *Department of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China.
Changquan Wang *Department of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China.
Wenyi Bai *State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.
Ju GaoDepartment of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China.
Yugao LiaoDepartment of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China.
Lei WangDepartment of Neurosurgery, Huanggang Central Hospital of Yangtze University, Hubei, China.
Xiangbo WuDepartment of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China.
Yu TianDepartment of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China.
Guanglin WangDepartment of Gastroenterology, Huanggang Central Hospital of Yangtze University, Hubei, China. wangguanglin@hgyy.org.cn.
Guangming XiaDepartment of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China. xiaguangming@hgyy.org.cn.
Jinhua WangDepartment of Neurology, Huanggang Central Hospital of Yangtze University, Hubei, China. wangjinhua@hgyy.org.cn.

Funding

2022BCE047 Hubei Provincial Key Research and Development Plan (Support local special Projects in the field of large health)
6 · The paper itself

Abstract

backgroundStroke is a crucial cause of morbidity and mortality worldwide. The regulator of G protein signaling 14 (RGS14) plays important roles in mediating multiple signaling pathways and various pathophysiological processes. However, the function of RGS14 in cerebral ischemic reperfusion injury (CIRI) remains unknown. METHODS AND

resultsIn this study, the roles of RGS14 during CIRI were studied in terms of gain- and loss-of-function experiments. Using RT-PCR, western blot, and TCC, HE, TUNEL, immunofluorescence, immunohistochemical staining, etc., we found that RGS14 significantly improved CIRI by reducing inflammation and apoptosis in both a mouse model of transient middle cerebral artery occlusion (t/MCAO) and a primary neuronal model of oxygen-glucose deprivation/reperfusion (OGD/R). In addition, mechanism studies have shown that RGS14 acts by inhibiting the activation of the TAK1-JNK/p38 signaling pathway, which was further confirmed using the TAK1 inhibitor (iTAK1), 5Z-7-oxyzeaenol, during OGD/R treatment of Adsh

conclusionsThese findings imply that RGS14 is a novel negative regulator and may serve as a potential therapeutic target for CIRI.

Indexed as

Brain IschemiaMAP Kinase Kinase KinasesMAP Kinase Signaling SystemReperfusion InjuryRGS ProteinsAnimalsApoptosisDisease Models, AnimalInfarction, Middle Cerebral ArteryMaleMAP Kinase Kinase Kinase 7MiceMice, Inbred C57BLNeuronsp38 Mitogen-Activated Protein KinasesSignal TransductionMAP Kinase Kinase Kinase 7MAP Kinase Kinase Kinasesp38 Mitogen-Activated Protein KinasesRGS Proteins

Identifiers

PMID41268900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.